Table 4.
Clinical characteristics of patients with Clostridium difficile infection (CDI) in periods before, during and after cessation of LP299v administration (n = 34). The above-mentioned periods lasted twelve months.
| Before LP299v Use (n = 18) | During LP299v Use (n = 2) | After Cessation of LP299v (n = 14) | |
|---|---|---|---|
| Age (years) | 57 ± 15 | 53 ± 16 | 55 ± 15 |
| Gender (M/F) | 9/9 | 2/0 | 11/3 |
| BMI (kg/m2) | 24 ± 4.5 | 23 ± 0 | 25 ± 3.7 |
| Diabetes mellitus (n/%) | (6/33%) | (2/100%) | (5/36%) |
| Chronic Kidney Disease (n/%) | (13/72%) | (1/50%) | (7/50%) |
| Dialysis (n/%) | (1/6%) | (0/0%) | (2/14%) |
| Systemic vasculitis (n/%) | (2/11%) | (0/0%) | (1/7%) |
| Liver cirrhosis (n/%) | (3/17%) | (1/50%) | (0/0%) |
| Inflammatory Bowel Disease (n/%) | (0/0%) | (0/0%) | (0/0%) |
| Cancer (n/%) | (3/17%) | (0/0%) | (1/7%) |
| Patients after organ transplantation (n/%) | (8/44%) | (2/100%) | (8/57%) |